| Texto completo | |
| Autor(es): |
Magalhaes, Taciani de Almeida
[1]
;
de Sousa, Graziella Ribeiro
[1]
;
Cruzeiro, Gustavo Alencastro Veiga
[2]
;
Tone, Luiz Gonzaga
[1, 2]
;
Valera, Elvis Terci
[2]
;
Borges, Kleiton Silva
[2]
Número total de Autores: 6
|
| Afiliação do(s) autor(es): | [1] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Genet, Av Bandeirantes 3900, BR-14048900 Sao Paulo - Brazil
[2] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Pediat, Av Bandeirantes 3900, BR-14048900 Sao Paulo - Brazil
Número total de Afiliações: 2
|
| Tipo de documento: | Artigo de Revisão |
| Fonte: | JOURNAL OF MOLECULAR MEDICINE-JMM; v. 98, n. 4 MAR 2020. |
| Citações Web of Science: | 0 |
| Resumo | |
Glioblastoma is the most common aggressive primary brain tumor. Standard care includes maximal safe surgical resection, radiation, and chemotherapy with temozolomide. However, the impact of this therapeutic approach on patient survival is disappointing and poor outcomes are frequently observed. Therefore, new therapeutic targets are needed to treat this potentially deadly tumor. Aurora kinases are one of today's most sought-after classes of therapeutic targets to glioblastoma therapy. They are a family of proteins composed of three members: Aurora-A, Aurora-B, and Aurora-C that play different roles in the cell division through regulation of chromosome segregation. Deregulation of these genes has been reported in glioblastoma and a progressive number of studies have shown that inhibition of these proteins could be a promising strategy for the treatment of this tumor. This review discusses the preclinical and early clinical findings on the potential use of the Aurora kinases as new targets for the treatment of glioblastoma. Key messages GBM is a very aggressive tumor with limited therapeutic options. Aurora kinases are a family of serine/threonine kinases implicated in GBM pathology. Aurora kinases are critical for glioblastoma cell growth, apoptosis, and chemoresistance. Inhibition of Aurora kinases has a synergistic or sensitizing effect with chemotherapy drugs, radiotherapy, or with other targeted molecules in GBM. Several Aurora kinase inhibitors are currently in clinical trials. (AU) | |
| Processo FAPESP: | 17/06511-8 - Investigação do complexo Smad2/3-YAP como fator quimioresistente em meduloblastoma SHH TP53 mutante |
| Beneficiário: | Gustavo Alencastro Veiga Cruzeiro |
| Modalidade de apoio: | Bolsas no Brasil - Pós-Doutorado |
| Processo FAPESP: | 16/19820-6 - Investigação de novos alvos terapêuticos a partir de redes transcricionais de genes do fuso mitótico associadas com vias de desenvolvimento embrionário no ependimoma: enfoque nos subgrupos moleculares de pior prognóstico |
| Beneficiário: | Taciani de Almeida Magalhães |
| Modalidade de apoio: | Bolsas no Brasil - Doutorado |
| Processo FAPESP: | 09/50118-2 - Investigacao de novos alvos terapeuticos envolvidos com a instabilidade genomica em glioblastoma. |
| Beneficiário: | Luiz Gonzaga Tone |
| Modalidade de apoio: | Auxílio à Pesquisa - Regular |
| Processo FAPESP: | 18/23372-4 - Estudo dos efeitos da desmetilação do DNA em genes associados às vias de desenvolvimento em Ependimomas pediátricos |
| Beneficiário: | Graziella Ribeiro de Sousa |
| Modalidade de apoio: | Bolsas no Brasil - Doutorado |